

Notification published in accordance with § 15 German Securities Trading Act (WpHG)

Record financial results in 2009 – All financial targets met or exceeded – Positive outlook for 2010

Group sales increased by 13% in constant currency and by 15% at actual rates to €14,164 million (2008: €12,336 million). Organic sales growth was 8%. Acquisitions contributed a further 5%. Currency translation had a positive impact of 2%.

Group operating income (EBIT) grew by 17% in constant currency and by 19% at actual rates to €2,054 million (2008 adjusted for special items related to the acquisition of APP Pharmaceuticals: €1,727 million).

Adjusted Group net income¹ grew both in constant currency and at actual rates by 14% to €514 million (2008 adjusted for special items related to the acquisition of APP Pharmaceuticals: €450 million). Adjusted earnings per ordinary share increased to €3.18 and adjusted earnings per preference share increased to €3.19 (2008 adjusted: ordinary share €2.85, preference share €2.86). This represents an increase of 12% for both share classes.

Net income² (including special items) was €494 million or €3.06 per ordinary share and €3.07 per preference share.

Based on the excellent financial results the Management Board will propose to the Supervisory Board a dividend increase of 7% to €0.75 per ordinary share (2008: €0.70) and €0.76 per preference share (2008: €0.71).

For 2010, Fresenius projects further improvements in its financial results: Sales growth in constant currency is projected to be in a 7 to 9% range. Adjusted net income¹ is expected to increase by 8 to 10% in constant currency.

The Group's US GAAP financial results as of December 31, 2009 and as of December 31, 2008 include the effects of mark-to-market accounting of the Mandatory Exchangeable Bonds (MEB) and the Contingent Value Rights (CVR)

related to the acquisition of APP Pharmaceuticals. Adjusted earnings represent the Group's business operations in the reporting period. In addition, the Group's US GAAP financial statements as of December 31, 2008 include several special items related to the acquisition of APP Pharmaceuticals.

¹ Net income attributable to Fresenius SE; adjusted for the effects of mark-to-market accounting of the Mandatory Exchangeable Bonds (MEB) and the Contingent Value Rights (CVR) related to the acquisition of APP Pharmaceuticals. Both are non-cash items.

² Net income attributable to Fresenius SE

(Financial statements according to US GAAP)

The Management Board

Bad Homburg v.d.H., February 24, 2010

End of note